Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy

Movement Disorders

Volumn 27, Issue 7, 2012, Pages 851-857

  Ishigami, Noriko ^a   Tokuda, Takahiko ^a   Ikegawa, Masaya ^a   Komori, Mika ^b   Kasai, Takashi ^a   Kondo, Takayuki ^c   Matsuyama, Yumiko ^d   Nirasawa, Takashi ^d   Thiele, Herbert ^d   Tashiro, Kei ^a   Nakagawa, Masanori ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Kitano Hospital   (Japan)

^d BRUKER DALTONIK GMBH   (Germany)

Author keywords

Biomarkers; Cerebrospinal fluid; Multiple system atrophy; Parkinson's disease; Proteomics

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SHY DRAGER SYNDROME; SUPPORT VECTOR MACHINE; VALIDATION PROCESS;

AGED; CEREBROSPINAL FLUID PROTEINS; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 84862679275     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24994     Document Type: Article

References (22)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
2. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178.
3. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
4. Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009; 24: 949-964.
5. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349: 162-166.
6. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713-726.
7. Abdo WF, De Jong D, Hendriks JC, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord 2004; 19: 571-579.
8. Brettschneider J, Petzold A, Sussmuth SD, et al. Neurofilament heavy-chain NfH (SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006; 21: 2224-2227.
9. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006; 9: 293-348.
10. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008; 129: 526-529.
11. Constantinescu R, Andreasson U, Li S, et al. Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism Relat Disord 2010; 16: 545-549.
12. Ketterlinus R, Hsieh SY, Teng SH, Lee H, Pusch W. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005;Suppl: 37-40.
13. Bosso N, Chinello C, Picozzi SC, et al. Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. Proteomics Clin Appl 2008; 2: 1036-1046.
14. Komori M, Matsuyama Y, Nirasawa T, et al. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol 2011;doi:10.1002/ana.22633.
15. Ivosev G, Burton L, Bonner R. Dimensionality reduction and visualization in principal component analysis. Anal Chem 2008; 80: 4933-4944.
16. Sekiyama E, Matsuyama Y, Higo D, et al. Applying magnetic bead separation/MALDI-TOF mass spectrometry to human tear fluid proteome analysis. J Proteomics Bioinformatics 2008; 1: 368-373.
17. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schiossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10: 230-240.
18. van Dijk KD, Teunissen CE, Drukarch B, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 2010; 39: 229-241.
19. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holyzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
20. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
21. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69: 570-580.
22. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769-794.